Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan

INTRODUCTION: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and da...

Descripción completa

Detalles Bibliográficos
Autores principales: Saida, Takahiko, Yokoyama, Kazumasa, Sato, Ryusuke, Makioka, Haruki, Iizuka, Yukihiko, Hase, Masakazu, Ling, Yan, Torii, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700906/
https://www.ncbi.nlm.nih.gov/pubmed/29119538
http://dx.doi.org/10.1007/s40120-017-0084-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700906/
https://www.ncbi.nlm.nih.gov/pubmed/29119538
http://dx.doi.org/10.1007/s40120-017-0084-6

Ejemplares similares